Skip to main content

Table 3 Summary statistics about each dose escalation method

From: Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies

A. Clinical trials dose toxicity curves

Dose escalation method

MTD selected by dose-escalation method (%)

True selected

Underestimated

Overestimated

< lowest dose

3 + 3

 

65.2

31.8

2.3

0.7

Extended CRM

Step-up

76.7

9.0

13.9

0.4

Dose-Linear

76.7

4.2

21.5

0.4

O’Quigley

76.6

11.6

14.4

0.4

Conservative

74.8

16.6

8.2

0.4

Sigmoidal

73.8

14.7

8.3

0.4

Aggressive

68.5

6.7

24.4

0.4

B. Theoretical dose toxicity curves

Dose escalation method

MTD selected by dose-escalation method (%)

True selected

Underestimated

Overestimated

< lowest dose

3 + 3

 

34.8

42.6

7.3

15.3

Extended CRM

Conservative

52.9

21.6

20.7

4.9

Sigmoidal

46.4

19.1

29.9

4.6

Step-up

42.8

22.1

30.1

5.1

O’Quigley

40.6

21.4

32.9

5.1

Aggressive

39.4

21.3

34.5

4.9

Dose-Linear

37.2

18.3

40.4

4.1

C. All dose toxicity curves

Dose escalation method

MTD selected by dose-escalation method (%)

True selected

Underestimated

Overestimated

< lowest dose

3 + 3

 

50.0

37.2

4.8

8.0

Extended CRM

Conservative

63.9

19.1

14.4

2.6

Sigmoidal

61.5

16.9

19.1

2.5

Step-up

59.7

15.5

22.0

2.8

O’Quigley

57.1

16.5

23.6

2.7

Dose-Linear

55.5

11.3

31.0

2.2

Aggressive

53.9

14.0

29.4

2.6